Title: Dose Optimization Study of Idelalisib in Follicular Lymphoma
Study Director: Study Director at Gilead Sciences
Description: Researchers are conducting a phase 3 study to establish a safe and effective dosing regimen of idelalisib for patients with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
The primary outcome measures are overall response rate and the incidence of grade 4 or higher treatment-emergent adverse events. Key secondary outcome measures include duration of response, overall response rate by week 24, progression-free survival, overall survival, and overall safety profile.
To be eligible for this study, patients must have a histologically confirmed diagnosis of grade 1, 2, or 3a B-cell FL. For a complete list of eligibility criteria, please refer to the reference.
This study is sponsored by Gilead Sciences.
Clinicaltrials.gov. Dose optimization study of idelalisib in follicular lymphoma. NCT02536300. Accessed November 15, 2021.
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
Want to read more?
Please login or register first to view this content.